Effector and regulatory B-cell imbalance in systemic sclerosis: cooperation or competition?

Area of Science:

• Immunology
• Rheumatology
• Cell Biology

Background:

• B cells are crucial in systemic sclerosis (SSc) pathogenesis, primarily studied for antibody production.
• Beyond antibody secretion, B cells influence immunity via antigen presentation and cytokine release.
• B cell subsets have opposing roles: regulatory B cells (Bregs) suppress inflammation, while effector B cells (Beffs) promote immune responses.

Purpose of the Study:

• To review the literature on B cell subsets in systemic sclerosis (SSc).
• To elucidate the dual roles of regulatory B cells (Bregs) and effector B cells (Beffs) in SSc pathogenesis.
• To discuss implications for SSc treatment strategies and biomarker discovery.

Main Methods:

• Literature review and synthesis of existing research on B cells in SSc.
• Analysis of the functional dichotomy between Bregs and Beffs.
• Examination of current and potential therapeutic interventions targeting B cells.

Main Results:

• Systemic sclerosis is characterized by insufficient or dysfunctional regulatory B cells (Bregs).
• Effector B cells (Beffs) contribute to SSc pathogenesis through pro-inflammatory cytokine production.
• Current B cell-targeting therapies may impact both Bregs and Beffs, potentially limiting efficacy.

Conclusions:

• Future SSc therapies could involve combined strategies: modulating Beffs and stimulating Bregs.
• Monitoring B cell subsets may yield novel biomarkers for predicting SSc relapse or progression.
• Understanding the interplay between Bregs and Beffs is key to advancing SSc treatment and management.